Pelthos Therapeutics and Castle Creek Biosciences combine forces to accelerate the development of a late-stage D-Fi franchise, aiming to address critical unmet needs in rare disease treatment.
Pelthos Therapeutics is undergoing a strategic combination with Castle Creek Biosciences to establish a specialized biotechnology entity. This merger centers on the advancement of the late-stage D-Fi franchise, which holds orphan drug designation for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
The company is focused on rare diseases, specifically leveraging the late-stage D-Fi franchise.
The lead indication is Dystrophic Epidermolysis Bullosa (DEB), which has received orphan drug designation.
Pelthos Therapeutics and Castle Creek Biosciences have announced a strategic combination to form a unified biotechnology entity. The new organization will prioritize the development of the late-stage D-Fi franchise, specifically targeting Dystrophic Epidermolysis Bullosa (DEB) under orphan drug designation.
The combined company focuses on advancing a late-stage D-Fi franchise, with a lead indication for Dystrophic Epidermolysis Bullosa (DEB) that has received orphan drug designation.